AI Article Synopsis
- PP2A is a tumor suppressor protein that plays a crucial role in regulating various cellular functions and maintaining cell survival.
- Endogenous inhibitors like CIP2A and SET undermine PP2A's ability to suppress tumors, leading to cancer development and resistance to treatment.
- Interestingly, using external small molecule inhibitors of PP2A can actually boost cancer treatment effectiveness, offering new strategies for tackling drug-resistant tumors and meriting further research.
Article Abstract
The protein phosphatase 2A (PP2A), a serine/threonine phosphatase, is recognized as a tumor suppressor involved in diverse cellular processes and essential for maintaining cell viability in vivo. However, endogenous inhibitors of PP2A such as cancerous inhibitor of PP2A (CIP2A) and endogenous nuclear protein inhibitor 2 of PP2A (SET) counteract the anticancer function of PP2A, promoting tumorigenesis, development, and drug resistance in tumors. Surprisingly though, contrary to conventional understanding, inhibition of the tumor suppressor gene PP2A with exogenous small molecule compounds can enhance the efficacy of cancer treatment and achieve superior tumor inhibition. Moreover, exogenous PP2A inhibitors resensitize cancers to treatment and provide novel therapeutic strategies for drug-resistant tumors, which warrant further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcp.31413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!